Chung-HanLeeMDPhD

Oncology • New York, NY

Genitourinary Oncology

Physician

Join to view full profile

Dr. Lee is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Lee's full profile

Already have an account?

Office
Memorial Sloan Kettering Cancer Center Westchester
500 Westchester Avenue
New York, NY 10021

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2011 - 2014
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2009 - 2011
University of Michigan Medical SchoolClass of 2009

Certifications & Licensure

FL State Medical License 2021 - Present
NJ State Medical License 2019 - 2025
NY State Medical License 2011 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

CB-839 With Everolimus vs. Placebo With Everolimus in Participants With Renal Cell Carcinoma (RCC) Start of enrollment: 2017 Sep 06
Completed
Phase 2
A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell Carcinoma Start of enrollment: 2018 Aug 13
Active, not recruiting
Phase 2

Publications & Presentations

PubMed

Corrigendum to "Cabozantinib Plus Nivolumab in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase II Trial" [Eur. Urol. 86(2) (2024) 90-94].
Kelly N Fitzgerald, Chung-Han Lee, Martin H Voss, Maria I Carlo, Andrea Knezevic
European Urology. 2025-01-01
Prospective Study of Patient, Nursing, and Oncology Provider Perspectives on Telemedicine Visits for Renal Cell Carcinoma Clinical Trials.
Sahil D Doshi, Andrea Knezevic, Carlene Gonzalez, Patricia Fischer, Robert Goodman
Clinical Genitourinary Cancer. 2024-11-13
1 citations
Lenvatinib plus Pembrolizumab Following Immune Checkpoint Inhibitor Treatment in Patients with Metastatic Clear Cell Renal Cell Carcinoma: Results from Study 111/KEYNO...
Chung-Han Lee, Amishi Yogesh Shah, Arpit Rao, Matthew H Taylor, Christopher Di Simone
European Urology. 2024-11-01

Lectures

Lenvatinib + pembrolizumab in patients with renal cell carcinoma: Updated results.
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

7 Myths About Kidney Cancer, DebunkedApril 19th, 2023
Second-Line Metastatic RCC Outcomes Similar Regardless of First-Line Immunotherapy Combo PartnerNovember 14th, 2022
What Is Kidney Cancer? Symptoms, Causes, Diagnosis, Treatment, and PreventionJune 12th, 2022
Join now to see all